Use of retinoic esters of hyaluronic acid for the differentiation of totipotent stem cells
AssigneeSintofarm S.P.A.
InventorsAlberto Perbellini, Carlo Ventura, Margherita Maioli
Life of this patent
Estimating the term…
Abstract
The present the invention relates to a new use of retinoic of hyaluronic acid, that exhibit pre-differentiating activity on totipotent stem cells. The invention also relates to a process to differentiate said stem cells and to select molecules capable of modulating the pro-differentiating activity of those esters.
Claims28
Use of retinoic esters of hyaluronic acid as stem cells pro-differentiating agents.
Use of polysaccharidic esters of retinoic acid for preparation of medicaments with cardiogenic pro-differentiating activity on stem cells.
Process for in vitro preparation of cardiomyocytes essentially comprising a step of incubation of stem cells with retinoic esters of hyaluronic acid and optionally a selection of the contractile units comprising said cardiomyocytes.
Process for preparation of an in vitro cell model for cardiogenic differentiation of stem cells, essentially comprising a step of incubation of said stem cells with retinoic esters of hyaluronic acid alone or in combination with other substances, in suitable culture medium.
A therapeutic method for treating heart failure in a patient in need of such a treatment characterised in that heterologous or autologous stem cells are treated “in vitro” or “ex vivo” with retinoic esters of hyaluronic acid.
Dependencies are inferred from the claim text.